These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33078727)

  • 21. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.
    Prapitpaiboon H; Mahachai V; Vilaichone RK
    Asian Pac J Cancer Prev; 2015; 16(10):4353-6. PubMed ID: 26028098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Helicobacter pylori eradication in Mexico with a levofloxacin-based scheme versus standard triple therapy: Results from an open-label, randomized, noninferiority phase iiib trial.
    Ladrón-de-Guevara L; Bornstein-Quevedo L; González-Huezo S; Castañeda-Romero B; Costa FG; di Silvio-López M
    Rev Gastroenterol Mex (Engl Ed); 2019; 84(3):274-283. PubMed ID: 30060902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
    Lu B; Wang J; Li J; Liu L; Chen Y
    Helicobacter; 2019 Apr; 24(2):e12566. PubMed ID: 30780194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
    Tsujimae M; Yamashita H; Hashimura H; Kano C; Shimoyama K; Kanamori A; Matsumoto K; Koizumi A; Momose K; Eguchi T; Fukuchi T; Fujita M; Okada A
    Digestion; 2016; 94(4):240-246. PubMed ID: 28030862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
    Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
    Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.
    Scaccianoce G; Hassan C; Panarese A; Piglionica D; Morini S; Zullo A
    Can J Gastroenterol; 2006 Feb; 20(2):113-7. PubMed ID: 16482238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
    Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
    Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
    Chen Q; Long X; Ji Y; Liang X; Li D; Gao H; Xu B; Liu M; Chen Y; Sun Y; Zhao Y; Xu G; Song Y; Yu L; Zhang W; Liu W; Graham DY; Lu H
    Aliment Pharmacol Ther; 2019 Jun; 49(11):1385-1394. PubMed ID: 31020673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori.
    Polat Z; Kadayifci A; Kantarcioglu M; Ozcan A; Emer O; Uygun A
    Eur J Intern Med; 2012 Mar; 23(2):165-8. PubMed ID: 22284248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
    Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
    Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication.
    Tepeš B; Vujasinović M; Šeruga M; Stefanovič M; Forte A; Jeverica S
    Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):676-83. PubMed ID: 26862930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection.
    Sereni G; Azzolini F; Camellini L; Formisano D; Decembrino F; Iori V; Tioli C; Cavina M; Di Mario F; Bedogni G; Sassatelli R
    World J Gastroenterol; 2012 Sep; 18(33):4542-8. PubMed ID: 22969227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial.
    Sahara S; Sugimoto M; Ichikawa H; Kagami T; Sakao Y; Ohashi N; Horio Y; Sugimoto K; Kato A; Furuta T; Yasuda H
    Digestion; 2018; 97(2):163-169. PubMed ID: 29310119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin.
    Song Z; Fu W; Zhou L
    BMC Gastroenterol; 2019 Jul; 19(1):132. PubMed ID: 31345165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes.
    Yang YJ; Wu CT; Ou HY; Lin CH; Cheng HC; Chang WL; Chen WY; Yang HB; Lu CC; Sheu BS
    Ann Med; 2017 Sep; 49(6):479-486. PubMed ID: 28266875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with
    Lee YD; Kim SE; Park SJ; Park MI; Moon W; Kim JH; Jung K; Song J
    Korean J Gastroenterol; 2020 Sep; 76(3):142-149. PubMed ID: 32969362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
    Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial.
    Romano M; Cuomo A; Gravina AG; Miranda A; Iovene MR; Tiso A; Sica M; Rocco A; Salerno R; Marmo R; Federico A; Nardone G
    Gut; 2010 Nov; 59(11):1465-70. PubMed ID: 20947881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China.
    Qian J; Ye F; Zhang J; Yang YM; Tu HM; Jiang Q; Shang L; Pan XL; Shi RH; Zhang GX
    Helicobacter; 2012 Dec; 17(6):478-85. PubMed ID: 23067317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection.
    Puig I; González-Santiago JM; Molina-Infante J; Barrio J; Herranz MT; Algaba A; Castro M; Gisbert JP; Calvet X
    Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28869699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.